Baird raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $32 from $28 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 report as its Firdapse and Agamree are poised for a strong 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals price target raised to $40 from $33 at Stephens
- Catalyst Pharmaceuticals Reports Record 2024 Financial Results
- Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges
- Closing Bell Movers: Snowflake up 11%, Nvidia little changed after earnings
- Catalyst Pharmaceuticals reports Q4 EPS 70c, consensus 55c